US Pharma MarketingThe post EASD 2026: Regeneron’s muscle preserver shows benefit at lower doses appeared first on Clinical Trials Arena.
EASD 2026: Regeneron’s muscle preserver shows benefit at lower doses
The COURAGE data sets Regeneron up to run a further Phase II trial of the muscle preserver in older patients. The COURAGE data sets Regeneron up to run a further Phase II trial of the muscle preserver in older patients. Regeneron is also developing a GLP-1RA through a partnership with Hansoh. Credit: lev radin / Shutterstock.com. Unlock FREE Access to Premium Content Discover exclusive forecasts, analyst insights, and in-depth clinical trials industry analysis across drug development, clinical research, and trial innovation. With a free Clinical Trials Arena profile, you can: Experience unmatched clarity with a single platform that combines unique…
The COURAGE data sets Regeneron up to run a further Phase II trial of the muscle preserver in older patients.
Source: Clinical Trials Arena